Better Therapeutics, Inc. (BTTX)

USD 0.0

(0.0%)

Market Cap (In USD)

5452.00

Revenue (In USD)

-

Net Income (In USD)

-39.76 Million

Avg. Volume

197.55 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-4-0.2725
PE
-
EPS
-
Beta Value
1.894
ISIN
US08773T1043
CUSIP
08773T104
CIK
1832415
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Frank L. Karbe
Employee Count
-
Website
https://www.bettertx.com
Ipo Date
2021-03-17
Details
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.